Allogeneic BMT for haematological disorders: Single centre experience of University Hospital Bratislava

Data on 65 sibling bone marrow transplantations (BMT) for various hematolog ical disorders are reported. 51 patients had leukemia, 8 severe aplastic an emia, 4 myelodysplastic syndrome, one suffered from non-Hodgkin lymphoma an d one from myeloid metaplasia. All but two patients have engrafted. Overall , 43 (66%) of 65 patients were alive 0,03 - 7,2 years (median not reached) as of June 23, 1997. Median time of observation was 13 months. Outcome of s tandard risk patients was significantly better than that of high risk patie nts (p=0,006). Our data confirm, that sibling BMT is an effective treatment modality with acceptable toxicity for younger patients with an early stage of serious hematological disorders.